Phage Therapy Market, By Product (Monophage therapy, Phage cocktails, Engineered/recombinant phages, Phage derived enzymes (e.g., endolysins), and Combination products (phage + antibiotic or adjunct)), By Target Pathogen (Gram negative bacteria (Escherichia coli, Pseudomonas aeruginosa, Salmonella spp., Klebsiella pneumoniae, Other Gram‐negative bacteria) and Gram positive bacteria (Gram‑positive bacteria, Staphylococcus aureus, Streptococcus spp., Other Gram‐positive bacteria, Mixed/other pathogens)), By Disease Indication (Urinary tract infections (UTIs), Skin and wound infections, Bone and joint/implant associated infections, Respiratory tract infections (including cystic fibrosis), Gastrointestinal infections, Bloodstream/sepsis infections, Biofilm related chronic infections, and Other indications), By Route of Administration (Oral, Topical/dermal, Injectable/intravenous (IV/IM), Inhalation/nebulized, Local instillation (e.g., bladder, wound cavity), and Other routes), By End User (Hospitals and specialty clinics, Research institutes and academic centers, Ambulatory care/outpatient clinics, and Others (Veterinary clinics)), By Geography (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa) - Growth Trends and Forecasts (2025-2032)